openPR Logo
Press release

Dilated Cardiomyopathy Therapeutics Market Research Report Forecast to 2020

10-02-2017 08:47 AM CET | Health & Medicine

Press release from: Transparency Market Research

/ PR Agency: Transparency Market Research
Dilated Cardiomyopathy Therapeutics Market Research Report

Transparency Market Research in a recent publication says competition in the global dilated cardiomyopathy therapeutics market is expected to grow as prominent companies strive to develop effective drugs for the treatment of dilated cardiomyopathy. For example, in February 2017, Myokardia Inc., a biopharmaceutical company, announced first time administer of MYK-491 to a batch of healthy subjects. MYK-491 is a treatment for dilated cardiomyopathy which is in Phase 1.

Keen players in the market are also focusing on collaborations, mergers, and acquisitions to consolidate their position. For example, in January 2015, Array BioPharma announced its plans of acquiring and obtaining world rights to encorafenib, which is a late stage oncology product from Novartis Pharma AG.

As per estimates by Transparency Market Research, the global dilated cardiomyopathy therapeutics market will be worth US$328.6 mn by the end of 2020 vis-à-vis revenue, expanding at a CAGR of 4.6% from 2014 to 2020.

The segment of angiotensin II receptor blockers led amongst other drug class segments in 2013. This was followed by the segment of beta blockers. The high acceptance of angiotensin II receptor blocks is attributed to their effective therapeutic action for the treatment of dilated cardiomyopathy.

Geography-wise, the report segments the global dilated cardiomyopathy therapeutics market into: North America, Asia Pacific, Europe, and Rest of the World. North America stood as the leading regional market in 2013 mainly due to high incidence of cardiac diseases. Asia Pacific is expected to take the lead in the upcoming years as changing lifestyle resulting in increasing incidence of cardiac diseases propels growth of dilated cardiomyopathy therapeutics market.

Request to view Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2293

The alarming rise in the prevalence of congestive heart failure is one of the prominent growth drivers of the global dilated cardiomyopathy market. Dilated cardiomyopathy accounts for 30-40% of total number of congestive heart failures each year. As per statistics of the World Health Organization, 17.5 million deaths in 2013 were related to heart disorders. The increasing incidence of congestive heart diseases has created an urgent need for effective drugs and treatment, thereby benefitting the dilated cardiomyopathy therapeutics market.

Due to this, several companies have initiated to carry out clinical trials so as to develop drugs specifically for dilated cardiomyopathy. At present, there is not a single FDA approved drug specifically for dilated cardiomyopathy because of which treatment administered is the same as that for congestive heart failure. For example, Array BioPharma is carrying out phase II study for its drug ARRY-371797 for the treatment of dilated cardiomyopathy. In addition, in 2014, Celladon Corporation completed its phase II study of MYDICAR to be used for the treatment of dilated cardiomyopathy. Success of these clinical trials will positively influence the global dilated cardiomyopathy therapeutics market.

Request to Download TOC of the Report: http://www.transparencymarketresearch.com/report-toc/2293

Studies reveal that angiotensin receptor blockers such as valsartan can reduce probability of hospitalization by 28%. These drugs have also been effective for patients of systolic heart disease by reduction of deaths by 37% and also for reduced frequency of hospitalization. These factors are furthering the expansion of the global dilated cardiomyopathy therapeutics market.

On the flip side, the side effects of dilated cardiomyopathy therapeutics is leading to their declined use. Moreover, availability of implantable devices and promising gene therapy are acting as roadblocks to the market.

Global Dilated Cardiomyopathy Therapeutics Market Market Report is available @ US$ 5795: http://www.transparencymarketresearch.com/checkout.php?rep_id=2293<ype=S

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact us:

Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Dilated Cardiomyopathy Therapeutics Market Research Report Forecast to 2020 here

News-ID: 749751 • Views:

More Releases from Transparency Market Research

Organ Transplant Rejection Medication Market Revenue to Cross $7.0 billion by 2031 to Rise at a Stellar CAGR of 3.9% | Transparency Market Research
Organ Transplant Rejection Medication Market Revenue to Cross $7.0 billion by 20 …
Organ transplantation stands as a beacon of hope for patients suffering from end-stage organ failure, offering a chance at extended life and improved quality of life. However, the success of organ transplantation hinges on effective immunosuppressive therapy to prevent rejection, a significant challenge faced by transplant recipients. The organ transplant rejection medication market plays a pivotal role in providing the pharmaceuticals necessary to mitigate rejection risk and ensure graft survival.
Atopic Dermatitis Drugs Market Revenue to Cross $28.2 billion by 2031 to Rise at a Stellar CAGR of 8.9% | Transparency Market Research
Atopic Dermatitis Drugs Market Revenue to Cross $28.2 billion by 2031 to Rise at …
Atopic dermatitis (AD), also known as eczema, is a chronic inflammatory skin condition characterized by intense itching, redness, and dryness. It affects millions of individuals worldwide, spanning across all age groups, from infants to adults. The atopic dermatitis drugs market plays a vital role in providing relief to patients suffering from this debilitating condition. This article delves into the dynamics of the atopic dermatitis drugs market, exploring key players, treatment
Penicillin G Acylase Market to Exceed USD 1.1 billion by 2031, Garnering 5.6% CA …
Penicillin G acylase (PGA) is an enzyme that plays a crucial role in the production of semi-synthetic penicillins, a class of antibiotics widely used in the treatment of bacterial infections. The Penicillin G acylase market is integral to the pharmaceutical industry, providing essential enzymes for the efficient and cost-effective production of antibiotics. This article delves into the dynamics of the Penicillin G acylase market, highlighting its significance, key players, emerging
Amyotrophic Lateral Sclerosis Treatment Market to Exceed USD 958.2 million by 2031, Garnering 5.5% CAGR | Transparency Market Research
Amyotrophic Lateral Sclerosis Treatment Market to Exceed USD 958.2 million by 20 …
The ALS treatment market encompasses various pharmaceuticals, medical devices, and supportive care interventions designed to alleviate symptoms and slow disease progression in ALS patients. These treatment modalities include medications such as riluzole and edaravone, non-invasive ventilation devices, feeding tubes, physical and occupational therapy, and palliative care services aimed at managing pain, spasticity, and respiratory insufficiency. Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a devastating neurodegenerative disorder characterized

All 5 Releases


More Releases for Dilated

Global Dilated Cardiomyopathy Market Insights, Forecast
Dilated Cardiomyopathy (DCM) refers to the cardiac hypertrophy, cannot effectively pump blood. Dilated Cardiomyopathy (DCM) is due to genetic or other disease caused by a heart disease, it respectively affect the ventricles of the heart and heart, the inferior vena chamber and the upper Chambers of the heart. The global Dilated Cardiomyopathy market is valued at 180 million US$ in 2018 and will reach 290 million US$ by the end
Dilated Cardiomyopathy Market Opportunity Analysis, 2026 – 2026
Dilated cardiomyopathy (DCM) is a condition in which the heart gets enlarged and is not able to efficiently pump blood. The reduced heart function can affect the functioning of other organs such as lungs, liver, and kidney. The heart muscles begin to dilate (stretches), which result in thinning and increased area of the chamber, further it spreads to the right ventricle and atria’s. As the heart chambers dilate, heart muscles
Dilated Cardiomyopathy Market – Global Industry Insights,2025
Dilated cardiomyopathy (DCM) is a condition in which the heart gets enlarged and is not able to efficiently pump blood. The reduced heart function can affect the functioning of other organs such as lungs, liver, and kidney. The heart muscles begin to dilate (stretches), which result in thinning and increased area of the chamber, further it spreads to the right ventricle and atria’s. As the heart chambers dilate, heart muscles
Dilated Cardiomyopathy - Pipeline Review, H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Dilated Cardiomyopathy - Pipeline Review, H1 2017, provides an overview of the Dilated Cardiomyopathy (Cardiovascular) pipeline landscape. Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is decreased because the heart's main pumping chamber, the left ventricle, is enlarged and weakened. Symptoms include Fatigue and weakness, Shortness of breath (dyspnea), lightheadedness, dizziness or fainting, persistent cough or wheezing,
Dilated Cardiomyopathy Therapeutics Market Research Report Forecast
A new market research report has been recently published by Transparency market research, a leading market intelligence firm. The research report, titled “Dilated Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020”, presents a market overview, market drivers, opportunities, challenges, product segmentation, and competitive landscape. The research report also features inputs and recommendations from industry experts and professionals to help the
Autoimmunity in myocarditis and dilated cardiomyopathy
Autoimmune Diseases: "Myocarditis is an acquired inflammatory condition involving the myocardial tissue. Although myocarditis is largely associated with viral infections, some cases remain idiopathic, while in others there is convincing evidence of autoimmune pathophysiology. Autoimmunity is influenced by genetic, immune, hormonal and environmental factors. Myocardial injury (due to infection, ischaemia, inflammation, toxins or other cardiotoxic factors) may trigger exposure to autoantigens, subsequently, initiating an autoimmune response, causing myocarditis and dilated